DCTH Stock Price, Delcath Systems, Inc. Quote, Chart

Market Summary

USD5.28+0.02

Market Closed

0.38%

DCTH Alerts

2 major insider buys recently.

DCTH Stock Price

View Fullscreen

DCTH RSI Chart

DCTH Valuation

Market Cap

129.7M

Price/Earnings (Trailing)

-2.72

Price/Sales (Trailing)

62.8

Price/Free Cashflow

-4.14

DCTH Price/Sales (Trailing)

DCTH Profitability

Operating Margin

69.25%

Return on Equity

-302.2%

Return on Assets

-123.48%

Free Cashflow Yield

-24.18%

DCTH Fundamentals

DCTH Revenue

Revenue (TTM)

2.1M

Rev. Growth (Yr)

-52.1%

Rev. Growth (Qtr)

-12.32%

DCTH Earnings

Earnings (TTM)

-47.7M

Earnings Growth (Yr)

-31.44%

Earnings Growth (Qtr)

45.25%

Breaking Down DCTH Revenue

Last 7 days

8.4%

Last 30 days

3.7%

Last 90 days

18.9%

Trailing 12 Months

-5.4%

How does DCTH drawdown profile look like?

DCTH Financial Health

Current Ratio

2.26

DCTH Investor Care

Shares Dilution (1Y)

144.49%

Diluted EPS (TTM)

-2.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.9M	2.6M	2.2M	2.1M
2022	3.2M	3.2M	3.3M	2.7M
2021	0	0	0	3.6M
2018	2.7M	2.9M	3.1M	0
2017	2.4M	2.4M	2.7M	2.7M
2016	1.7M	1.7M	1.8M	2.0M
2015	1.2M	1.4M	1.6M	1.7M
2014	720.0K	971.0K	1.1M	1.1M
2013	457.3K	568.5K	679.8K	791.0K
2012	0	0	0	346.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Delcath Systems, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 19, 2024	muir kevin	acquired	50,000	3.72	13,441	gm interventional oncology
Mar 19, 2024	hoffman david l.	acquired	74,998	3.72	20,161	gen'l counsel, cco & secy
Mar 19, 2024	michel gerard j	acquired	150,002	3.72	40,323	chief executive officer
Mar 19, 2024	salamon steven a j	bought	100,001	3.72	26,882	-
Mar 19, 2024	vukovic vojo	acquired	100,001	3.72	26,882	chief medical officer
Mar 19, 2024	pennell sandra	acquired	99,997	3.72	26,881	svp of finance, pfo and pao
Mar 19, 2024	aharon gil	bought	100,001	3.72	26,882	-
Dec 12, 2023	vukovic vojo	bought	120,000	3.00	40,000	chief medical officer
Dec 08, 2023	michel gerard j	bought	99,960	2.94	34,000	chief executive officer
Nov 17, 2023	rosalind advisors, inc.	bought	240,410	2.4041	100,000	-

Which funds bought or sold DCTH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	4.00	29.00	-%
Apr 25, 2024	Rosalind Advisors, Inc.	unchanged	-	633,685	4,955,210	4.63%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-20.83	-5,000	52,000	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	61.00	477	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	1.00	5.00	-%
Apr 22, 2024	Vivo Capital, LLC	added	94.9	4,392,780	7,950,380	0.62%
Mar 11, 2024	VANGUARD GROUP INC	added	19.71	405,510	2,171,550	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-63,000	-	-%
Feb 14, 2024	BVF INC/IL	unchanged	-	107,377	4,060,780	0.10%
Feb 14, 2024	STATE STREET CORP	unchanged	-	7,563	286,029	-%

Are Funds Buying or Selling DCTH?

Are funds buying DCTH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DCTH

No. of Funds

DCTH Alerts

2 major insider buys recently.

Unveiling Delcath Systems, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 25, 2024	rosalind advisors, inc.	9.9%	1,151,907	SC 13D/A
Feb 14, 2024	biotechnology value fund l p	6.2%	1,433,024	SC 13G/A
Feb 13, 2024	vivo opportunity fund holdings, l.p.	9.99%	2,708,579	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	0.9%	208,333	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	0.0%	0	SC 13G/A
Jan 09, 2024	hirschman orin	6.8%	1,539,638	SC 13G
Nov 28, 2023	rosalind advisors, inc.	9.9%	1,098,143	SC 13D/A
Aug 16, 2023	soleus capital master fund, l.p.	5.3%	806,420	SC 13G
Jun 26, 2023	stonepine capital management, llc	8.7%	976,008	SC 13G
Jun 22, 2023	biotechnology value fund l p	6.5%	1,012,121	SC 13G

Recent SEC filings of Delcath Systems, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	8-K	Current Report
Apr 12, 2024	ARS	ARS
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	DEFA14A	DEFA14A
Mar 26, 2024	10-K	Annual Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	D	D
Mar 25, 2024	SC 13D/A	13D - Major Acquisition
Mar 20, 2024	3	Insider Trading
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to Delcath Systems, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

Delcath Systems, Inc. News

Latest updates

Delcath Systems, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4
Revenue	24.2%	539	434	495	597	639	906	797	378	1,171	824	858	702	704	684	584	743	676	435	511	370	439
Cost Of Revenue	28.6%	171	133	150	181	238	235	180	33.00	130	233	220	147	-	-	-	-	-	-	-	-	-
Gross Profit	22.3%	368	301	345	416	401	671	617	345	1,979	591	638	555	-	-	-	-	-	-	-	-	-
Operating Expenses	7.5%	11,672	10,857	8,342	8,741	8,256	8,844	10,103	8,685	6,636	6,385	6,730	8,058	-	-	-	-	-	-	-	-	-
S&GA Expenses	12.4%	6,963	6,195	4,787	4,165	3,825	4,779	4,497	4,204	3,017	2,279	2,641	2,366	-	-	-	-	-	-	-	-	-
R&D Expenses	1.0%	4,709	4,662	3,555	4,576	4,431	4,065	5,606	4,481	3,619	4,106	4,089	5,692	-	-	-	-	-	-	-	-	-
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-7.58*	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0.6%	337	335	296	491	536	495	431	411	421	-	-	-	1,379	5,042	6,916	-	7,744	4,963	-	-	-
EBT Margin	-	-	-	-	-	-	-	-	-	-	-14.61*	-	-	-	-	-	-	-	-	-	-	-
Net Income	45.3%	-11,136	-20,340	-7,202	-9,000	-8,472	-8,877	-10,159	-9,000	-5,347	-8,880	-6,658	7,185	-	-	-	-	-	-	-	-	-
Net Income Margin	-11.0%	-23.09*	-20.80*	-12.73*	-12.42*	-13.42*	-10.27*	-9.98*	-8.64*	-7.21*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	10.1%	-8,246	-9,172	-9,688	-4,264	-7,359	-5,247	-6,089	-6,464	-6,028	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-18.8%	39.00	48.00	21.00	31.00	18.00	20.00	21.00	27.00	33.00	34.00	25.00	32.00	35.00	17.00	20.00	10.00	14.00	19.00	6.00	6.00	7.00
Current Assets	-19.4%	37.00	46.00	19.00	29.00	16.00	18.00	19.00	25.00	31.00	32.00	23.00	30.00	32.00	14.00	19.00	8.00	13.00	17.00	3.00	3.00	6.00
Cash Equivalents	-68.7%	13.00	40.00	15.00	24.00	8.00	10.00	10.00	16.00	23.00	25.00	19.00	27.00	29.00	11.00	16.00	5.00	10.00	15.00	0.00	0.00	3.00
Inventory	24.6%	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-1.6%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-0.1%	23.00	23.00	21.00	25.00	24.00	25.00	24.00	22.00	21.00	23.00	10.00	12.00	13.00	13.00	13.00	18.00	21.00	38.00	35.00	30.00	22.00
Current Liabilities	17.7%	16.00	14.00	11.00	13.00	15.00	14.00	12.00	9.00	6.00	5.00	6.00	10.00	10.00	11.00	8.00	13.00	16.00	32.00	31.00	25.00	18.00
Shareholder's Equity	-36.2%	16.00	25.00	-	-	-5.86	-	-	5.00	12.00	12.00	15.00	20.00	22.00	3.00	8.00	-	-	-	-	-	-
Retained Earnings	-2.3%	-505	-494	-473	-466	-457	-447	-438	-429	-420	-415	-408	-402	-395	-388	-383	-379	-371	-383	-357	-351	-344
Additional Paid-In Capital	0.4%	521	519	473	453	452	442	436	434	433	427	424	422	417	392	391	371	365	365	328	328	329
Accumulated Depreciation	-	5.00	-	-	-	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	15.6%	23.00	20.00	15.00	10.00	10.00	9.00	8.00	8.00	8.00	8.00	7.00	6.00	6.00	-	-	-	-	-	-	-	-
Float	-	-	-	82.00	-	-	-	31,948	-	-	-	87.00	-	-	-	34.00	-	-	-	2.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	10.3%	-8,227	-9,173	-9,636	-4,264	-7,359	-5,179	-6,037	-6,375	-6,029	-4,906	-7,102	-4,567	-5,040	-4,746	-7,853	-5,229	-5,367	-12,360	-3,192	-2,770	-1,838
Cashflow From Investing	-1967100.0%	-19,670	1.00	-40.00	-	-	-68.00	-52.00	-89.00	1.00	-56.00	-79.00	-9.00	-74.00	-487	-41.00	-180	-22.00	-	-	-2.00	-17.00
Cashflow From Financing	-100.0%	1.00	35,076	7.00	16,694	5,247	4,896	-	-	3,927	14,502	17.00	2,376	22,883	223	19,366	-117	-25.00	26,461	3,319	550	-4,288
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,160	-

DCTH Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenues	$ 2,065	$ 2,719
Cost of goods sold	(635)	(686)
Gross profit	1,430	2,033
Operating expenses:
Research and development expenses	17,502	18,583
Selling, general and administrative expenses	22,110	17,303
Total operating expenses	39,612	35,886
Operating loss	(38,182)	(33,853)
Change in fair value of warrant liability	(7,998)	0
Interest expense, net	(1,439)	(2,685)
Other income (expense)	(59)	30
Net loss	(47,678)	(36,508)
Comprehensive (loss) income:
Unrealized gain on investments	157	0
Foreign currency translation adjustments	61	101
Total comprehensive loss	$ (47,460)	$ (36,407)
Common share data:
Basic loss per common share (in dollars per share)	$ (2.94)	$ (4.12)
Diluted loss per common share (in dollars per share)	$ (2.94)	$ (4.12)
Weighted average number of basic shares outstanding (in shares)	16,229,931	8,864,615
Weighted average number of diluted shares outstanding (in shares)	16,229,931	8,864,615
Product revenue
Total revenues	$ 2,065	$ 2,548
Other revenue
Total revenues	$ 0	$ 171

DCTH Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 12,646	$ 7,671
Restricted cash	50	4,151
Short-term investments	19,808	0
Accounts receivable, net	241	366
Inventories	3,322	1,998
Prepaid expenses and other current assets	1,091	1,969
Total current assets	37,158	16,155
Property, plant and equipment, net	1,352	1,422
Right-of-use assets	103	285
Total assets	38,613	17,862
Current liabilities
Accounts payable	1,012	2,018
Accrued expenses	5,249	4,685
Lease liabilities, current	37	186
Loan payable, current	5,239	7,846
Convertible notes payable, current	4,911	0
Total current liabilities	16,448	14,735
Warrant Liability	5,548	0
Other liabilities, non-current	840	1,144
Loan payable, non-current	0	3,070
Convertible notes payable, non-current	0	4,772
Total liabilities	22,836	23,721
Commitments and contingencies (see note 15)
Stockholders’ equity (deficit)
Preferred stock, $.01 par value; 10,000,000 shares authorized; 24,819 and 11,357 shares issued and outstanding at December 31, 2023 and 2022, respectively	0	0
Common stock, $.01 par value; 80,000,000 shares authorized; 22,761,554 shares and 10,046,571 shares issued and outstanding at December 31, 2023 and 2022, respectively	228	100
Additional paid-in capital	520,576	451,608
Accumulated deficit	(505,162)	(457,484)
Accumulated other comprehensive income (loss)	135	(83)
Total stockholders’ equity (deficit)	15,777	(5,859)
Total liabilities and stockholders’ equity	$ 38,613	$ 17,862

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

CEO	Mr. Gerard J. Michel MBA, MS
WEBSITE	delcath.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	52

Delcath Systems, Inc. Frequently Asked Questions

What is the ticker symbol for Delcath Systems, Inc.? What does DCTH stand for in stocks?

DCTH is the stock ticker symbol of Delcath Systems, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Delcath Systems, Inc. (DCTH)?

As of Fri Apr 26 2024, market cap of Delcath Systems, Inc. is 129.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DCTH stock?

You can check DCTH's fair value in chart for subscribers.

What is the fair value of DCTH stock?

You can check DCTH's fair value in chart for subscribers. The fair value of Delcath Systems, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Delcath Systems, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DCTH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Delcath Systems, Inc. a good stock to buy?

The fair value guage provides a quick view whether DCTH is over valued or under valued. Whether Delcath Systems, Inc. is cheap or expensive depends on the assumptions which impact Delcath Systems, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DCTH.

What is Delcath Systems, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, DCTH's PE ratio (Price to Earnings) is -2.72 and Price to Sales (PS) ratio is 62.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DCTH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Delcath Systems, Inc.'s stock?

In the past 10 years, Delcath Systems, Inc. has provided -0.813 (multiply by 100 for percentage) rate of return.